Novo Nordisk’s study showing a new drug wasn’t as good as a rival’s led one sell-side analyst to downgrade the stock for the first time in five years.
Analyst says he’s thrown in the towel on Novo Nordisk after latest setback
Related Posts
Popular News
Latest News
BlockShoals Explains Binance’s Philippine Regulatory Status
Binance is allowed to provide crypto trading access to users in the Philippines through its arrangement with BlockShoals Technologies, but...
Trading in French server company suspended after short seller’s accusations trigger stock collapse
Trading of ordinary shares in the French technology company have been suspended following allegations from a short seller.
BMW prepares for talks with staff in wake of profit warning
BMW prepares for talks with staff in wake of profit warning
11 Santa Fe Airbnbs That Embody “The City Different”
Santa Fe is called "The City Different" for good reason. With its many unique neighborhoods, Southwestern pizzazz, and Indigenous heritage,...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.